583 related articles for article (PubMed ID: 16052578)
1. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
3. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
5. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
6. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
7. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
8. [Anti-TNF-alpha treatment and spondyloarthropathies].
Braun Y; Balbir-Gurman A
Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
[TBL] [Abstract][Full Text] [Related]
9. [The role of biologic agents in the therapy of ankylosing spondylitis].
Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
12. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
13. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
16. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
17. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Guignard S; Gossec L; Salliot C; Ruyssen-Witrand A; Luc M; Duclos M; Dougados M
Ann Rheum Dis; 2006 Dec; 65(12):1631-4. PubMed ID: 16901960
[TBL] [Abstract][Full Text] [Related]
19. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
20. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]